Skip to main content

Table 1 Demographic data and clinical characteristics of the study subjects

From: Risk of immune-mediated inflammatory diseases in newly diagnosed ankylosing spondylitis patients: a population-based matched cohort study

  Non-AS AS  
(n = 309,110) (n = 30,911) P value
Age, years (mean ± SD) 42 ± 17 42 ± 17 1.00
Sex    1.00
 Female 114,560 (37.1) 11,456 (37.1)  
 Male 194,550 (62.9) 19,455 (62.9)  
CCI (mean ± SD) 0.22 ± 0.74 0.35 ± 0.89 < 0.01
CCI group    < 0.01
 0 269,864 (87.3) 24,208 (78.3)  
 ≥ 1 39,246 (12.7) 6703 (21.7)  
Prior IMID
 Acute anterior uveitis 604 (0.194) 1695 (5.483) < 0.01
 Psoriasis 1019 (0.330) 455 (1.472) < 0.01
 Inflammatory bowel disease 71 (0.023) 18 (0.058) < 0.01
 Crohn’s disease 41 (0.013) 7 (0.023) 0.19
 Ulcerative colitis 38 (0.012) 13 (0.042) < 0.01
 Systemic lupus erythematosus 193 (0.062) 79 (0.256) < 0.01
 Sjögren’s syndrome 137 (0.044) 99 (0.320) < 0.01
 Rheumatoid arthritis 401 (0.13) 345 (1.116) < 0.01
 Systemic sclerosis 20 (0.006) 10 (0.032) < 0.01
 Dermatomyositis 12 (0.004) 7 (0.023) < 0.01
 Polymyositis 11 (0.004) 1 (0.003) 0.93
 Thromboangiitis obliterans 1 (0.0003) 1 (0.003) < 0.01
 Behcet’s disease 18 (0.006) 24 (0.078) < 0.01
 Pemphigus 16 (0.005) 2 (0.006) 0.77
 Sarcoidosis 13 (0.004) 6 (0.019) < 0.01
 Vitiligo 144 (0.047) 30 (0.097) < 0.01
  1. Data are presented as number (%) unless specified otherwise
  2. Abbreviations: AS ankylosing spondylitis, SD standard deviation, CCI Charlson comorbidity index, IMID immune-mediated inflammatory disease